Processa Pharmaceuticals, Inc.

NASDAQ (USD): Processa Pharmaceuticals, Inc. (PCSA)

Last Price

1.80

Today's Change

+0.04 (2.27%)

Day's Change

1.76 - 1.83

Trading Volume

9,314

Overview

Market Cap

5 Million

Shares Outstanding

2 Million

Avg Volume

1,456,509

Avg Price (50 Days)

2.11

Avg Price (200 Days)

5.40

PE Ratio

-0.21

EPS

-8.48

Earnings Announcement

08-Aug-2024

Previous Close

1.76

Open

1.76

Day's Range

1.76 - 1.83

Year Range

1.4 - 18.0

Trading Volume

9,314

Price Change Highlight

1 Day Change

2.27%

5 Day Change

-9.09%

1 Month Change

-16.28%

3 Month Change

-15.09%

6 Month Change

-80.85%

Ytd Change

-74.54%

1 Year Change

-83.64%

3 Year Change

-98.58%

5 Year Change

-99.49%

10 Year Change

-99.93%

Max Change

-99.93%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment